Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Human Microbiome Therapeutics Market By Product Type, By Application, and Geography
Human Microbiome Therapeutics Market size was valued at US$ 456.2 million in 2022 and is poised to grow at a significant CAGR of 22.3% from 2023-29. The microbiome is the collective genomes of the microbes consisting of bacteria, bacteriophage, fungi, protozoa, and viruses that live inside the human body. The human microbiota is made of around 10-100 trillion symbiotic microbial cells harbored by each person, primarily in the human gut. The presence of a healthy microbiome is necessary to perform specific sets of biomolecular functions in each biochemical environment across the body, especially in stomach flora and intestinal flora. Gut microbes respond quickly to a change in diet, which means the composition of the microbiome can be changed by changing eating habits.
The increasing applications of microbiome-based products in human health and technological advancements in the microbiome industry are driving the global human microbiome market growth. Also, the increasing number of digestive disorders is fueling the growth of the overall human microbiome market. For example, according to WHO, digestive disorders accounted for 375,170 deaths, 215,168 deaths in men, and 160,002 deaths in women, a crude rate of 37.2 deaths per 100,000 population (43.3 deaths/100,000 in men and 31.3 deaths/100,000 in women) worldwide in 2019. Hence, the increasing focus on human microbiome therapeutics development is the major driver in the global market. Moreover, the launches of new products in this market and collaboration between public-private organizations are influencing the global human microbiome market trend due to various high growth opportunities. The global key players are continuously driving market growth through mergers, acquisitions, and innovations.
However, stringent government regulations in the industry and the lack of awareness about human microbiome products may hamper the global human microbiome market growth. Geographically, North America held the major market share in the global human microbiome market and is expected to dominate the global market in the forecasted years.
Study Period
2024-2030Base Year
2023CAGR
22.3%Largest Market
North AmericanFastest Growing Market
Asia-Pacific
The increasing focus on microbiome therapeutics development is driving the global human microbiome market. Human gut microbiomes are very important for healthy digestive systems. In the last decade, microbiome therapy has gained widespread importance due to the increasing rate of digestive problems, unhealthy lifestyles, and increasing consumption of junk food and fast food. According to Pan American Health Organization (PAHO), digestive disorders accounted for 375,170 deaths, 215,168 deaths in men, and 160,002 deaths in women in 2019. Hence, it will boost the global human microbiome market growth in the forecasted years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 456.2 million |
Market CAGR |
22.3% |
By Product Type |
|
By Application |
|
By Region |
|
Download Free Sample Report
The human microbiome market size was valued at US$ 456.2 million in 2022
Enterome Bioscience, Seres Therapeutics, 4D pharma, Second Genome, Vedanta Biosciences, Ferring Pharmaceuticals, ViThera Pharmaceuticals, BiomX, DuPont, Kaleido, YSOPIA Bioscience, Metabiomics, Yakult Honsha, OptiBiotix
Global is the fastest-growing region for human microbiome market
1. Executive Summary |
2. Global Human Microbiome Therapeutics Market Introduction |
2.1. Global Human Microbiome Therapeutics Market – Taxonomy |
2.2. Global Human Microbiome Therapeutics Market – Definitions |
2.2.1. Product Type |
2.2.2. Application |
3. Global Human Microbiome Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Human Microbiome Therapeutics Market Dynamic Factors - Impact Analysis |
3.6. Global Human Microbiome Therapeutics Market – Competition Landscape |
4. Global Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Human Microbiome Therapeutics Market, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1. Prebiotics |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Probiotics |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Symbiotics |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Xenobiotics |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Human Microbiome Therapeutics Market Forecast, By Application, 2018 - 2022 and Forecast, 2023 - 2029 |
6.1. Obesity |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Diabetes |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Autoimmune Disorders |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Cancer |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Gastrointestinal Disorders |
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Central Nervous System Disorders |
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Skin Care and Oral Care |
6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
6.8. Others |
6.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.8.3. Market Opportunity Analysis |
7. Global Human Microbiome Therapeutics Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia-Pacific |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Middle East and Africa |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Region,2023 - 2029 |
8. North America Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1. By Product Type Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Prebiotics |
8.1.2. Probiotics |
8.1.3. Symbiotics |
8.1.4. Xenobiotics |
8.2. Application Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
8.2.1. Obesity |
8.2.2. Diabetes |
8.2.3. Autoimmune Disorders |
8.2.4. Cancer |
8.2.5. Gastrointestinal Disorders |
8.2.6. Central Nervous System Disorders |
8.2.7. Skin Care and Oral Care |
8.2.8. Others |
8.3. Country Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
8.3.1. USA |
8.3.2. Canada |
8.4. North America Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Country,2023 - 2029 |
8.5. North America Human Microbiome Therapeutics Market Dynamics – Trends |
9. Europe Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1. By Product Type Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Prebiotics |
9.1.2. Probiotics |
9.1.3. Symbiotics |
9.1.4. Xenobiotics |
9.2. Application Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Obesity |
9.2.2. Diabetes |
9.2.3. Autoimmune Disorders |
9.2.4. Cancer |
9.2.5. Gastrointestinal Disorders |
9.2.6. Central Nervous System Disorders |
9.2.7. Skin Care and Oral Care |
9.2.8. Others |
9.3. Country Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Germany |
9.3.2. UK |
9.3.3. France |
9.3.4. Spain |
9.3.5. Italy |
9.3.6. Russia |
9.3.7. Poland |
9.3.8. Rest of Europe |
9.4. Europe Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Country,2023 - 2029 |
9.5. Europe Human Microbiome Therapeutics Market Dynamics – Trends |
10. Asia-Pacific Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
10.1. By Product Type Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Prebiotics |
10.1.2. Probiotics |
10.1.3. Symbiotics |
10.1.4. Xenobiotics |
10.2. Application Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Obesity |
10.2.2. Diabetes |
10.2.3. Autoimmune Disorders |
10.2.4. Cancer |
10.2.5. Gastrointestinal Disorders |
10.2.6. Central Nervous System Disorders |
10.2.7. Skin Care and Oral Care |
10.2.8. Others |
10.3. Country Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Japan |
10.3.2. China |
10.3.3. India |
10.3.4. ASEAN |
10.3.5. Australia & New Zealand |
10.3.6. Rest of Asia-Pacific |
10.4. Asia-Pacific Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Country,2023 - 2029 |
10.5. Asia-Pacific Human Microbiome Therapeutics Market Dynamics – Trends |
11. Latin America Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
11.1. By Product Type Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Prebiotics |
11.1.2. Probiotics |
11.1.3. Symbiotics |
11.1.4. Xenobiotics |
11.2. Application Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Obesity |
11.2.2. Diabetes |
11.2.3. Autoimmune Disorders |
11.2.4. Cancer |
11.2.5. Gastrointestinal Disorders |
11.2.6. Central Nervous System Disorders |
11.2.7. Skin Care and Oral Care |
11.2.8. Others |
11.3. Country Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Brazil |
11.3.2. Mexico |
11.3.3. Argentina |
11.3.4. Rest of Latin America |
11.4. Latin America Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Country,2023 - 2029 |
11.5. Latin America Human Microbiome Therapeutics Market Dynamics – Trends |
12. Middle East and Africa Human Microbiome Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
12.1. By Product Type Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Prebiotics |
12.1.2. Probiotics |
12.1.3. Symbiotics |
12.1.4. Xenobiotics |
12.2. Application Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Obesity |
12.2.2. Diabetes |
12.2.3. Autoimmune Disorders |
12.2.4. Cancer |
12.2.5. Gastrointestinal Disorders |
12.2.6. Central Nervous System Disorders |
12.2.7. Skin Care and Oral Care |
12.2.8. Others |
12.3. Country Analysis 2018 - 2022 and Forecast, 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Gulf Cooperation Council (GCC) Countries |
12.3.2. Israel |
12.3.3. South Africa |
12.3.4. Rest of MEA |
12.4. MEA Human Microbiome Therapeutics Market - Opportunity Analysis Index, By Product Type, Application, and Country,2023 - 2029 |
12.5. MEA Human Microbiome Therapeutics Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Application & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Invivo Healthcare |
13.2.2. MicroBiome Therapeutics LLC |
13.2.3. Evolve Biosystems |
13.2.4. Enterome SA |
13.2.5. Seres Therapeutics |
13.2.6. Finch Therapeutics |
13.2.7. Second Genome Therapeutics |
13.2.8. ViThera Pharmaceuticals Inc. |
13.2.9. LNC Therapeutics SA |
13.2.10. CoreBiome, Inc. |
14. Research Methodology |
15. Key Assumptions and Acronyms |
Key Market Players